Cancer remains the second leading cause of death in the industrialized world and its incidence is growing.
But if detected early enough, many forms of the disease can be effectively treated.1
The prevalence of cancer in India is estimated to be 3.9 million people with a reported incidence of 1 1 million in 2015.3
The stage of diagnosis in India is generally more delayed compared to other countries with only 20-30% of cancers being diagnosed in Stages I and II, which is less than half of that in the US, UK and China.3
Breast and cervical cancers among women and head and neck, lung and gastrointestinal cancers among men represent >60% of the incidence burden. India has nearly three times the incidence of US and China for head and neck and cervical cancers. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. As many as 2,500 persons die every day due to tobacco-related diseases in India4. One woman dies of cervical cancer every 8 minutes in India.
The overall cancer market in India is estimated to be $460 million in 2016, growing at a CAGR of 14% from 2013-16 and is one of the fastest emerging segments across all therapy areas. The Indian oncology market is the fourth largest in volume and 8th largest in value. This is due to availability of branded generics at a cheaper price hence there is a disparity between value and volume sale in India.2
2) IPSOS MAT 2016 report